Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesLong-Term Debt IssuancesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inhibrx Biosciences (INBX) Cash from Operations: 2023-2025

Historic Cash from Operations for Inhibrx Biosciences (INBX) over the last 2 years, with Sep 2025 value amounting to -$33.8 million.

  • Inhibrx Biosciences' Cash from Operations fell 11.70% to -$33.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$143.4 million, marking a year-over-year increase of 30.90%. This contributed to the annual value of -$194.4 million for FY2024, which is 0.57% down from last year.
  • Per Inhibrx Biosciences' latest filing, its Cash from Operations stood at -$33.8 million for Q3 2025, which was down 12.92% from -$30.0 million recorded in Q2 2025.
  • Inhibrx Biosciences' 5-year Cash from Operations high stood at -$30.0 million for Q2 2025, and its period low was -$63.0 million during Q1 2024.
  • In the last 3 years, Inhibrx Biosciences' Cash from Operations had a median value of -$43.7 million in 2024 and averaged -$45.0 million.
  • Data for Inhibrx Biosciences' Cash from Operations shows a peak YoY increase of 47.78% (in 2025) and a maximum YoY decrease of 11.70% (in 2025) over the last 5 years.
  • Inhibrx Biosciences' Cash from Operations (Quarterly) stood at -$56.8 million in 2023, then rose by 23.06% to -$43.7 million in 2024, then dropped by 11.70% to -$33.8 million in 2025.
  • Its last three reported values are -$33.8 million in Q3 2025, -$30.0 million for Q2 2025, and -$35.9 million during Q1 2025.